JPMorgan Chase & Co. Has $345,000 Holdings in Smith & Nephew plc (NYSE:SNN)

JPMorgan Chase & Co. lessened its holdings in Smith & Nephew plc (NYSE:SNN) by 57.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,020 shares of the medical equipment provider’s stock after selling 18,957 shares during the period. JPMorgan Chase & Co.’s holdings in Smith & Nephew were worth $345,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of SNN. Principal Securities Inc. grew its holdings in shares of Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 691 shares during the last quarter. R Squared Ltd acquired a new stake in Smith & Nephew in the fourth quarter valued at approximately $41,000. Hara Capital LLC grew its stake in shares of Smith & Nephew by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock worth $73,000 after buying an additional 718 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Smith & Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider’s stock valued at $144,000 after acquiring an additional 1,213 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew Price Performance

Shares of SNN opened at $28.59 on Friday. The company has a market capitalization of $12.52 billion, a price-to-earnings ratio of 13.24, a price-to-earnings-growth ratio of 1.26 and a beta of 0.71. The business has a 50-day moving average of $27.65 and a 200-day moving average of $26.33. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. Smith & Nephew plc has a 1 year low of $23.69 and a 1 year high of $31.72.

Smith & Nephew Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be given a dividend of $0.447 per share. The ex-dividend date of this dividend is Friday, March 28th. This is a boost from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. Smith & Nephew’s dividend payout ratio is 41.20%.

Wall Street Analysts Forecast Growth

SNN has been the topic of a number of research reports. Canaccord Genuity Group boosted their price objective on Smith & Nephew from $27.00 to $28.00 and gave the stock a “hold” rating in a research report on Thursday. UBS Group downgraded Smith & Nephew from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. HSBC cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. Finally, Hsbc Global Res lowered shares of Smith & Nephew from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Six research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.00.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.